Lyra Therapeutics Inc [LYRA] stock is trading at $0.33, up 14.74%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LYRA shares have gain 3.22% over the last week, with a monthly amount glided 22.59%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Lyra Therapeutics Inc [NASDAQ: LYRA] stock has seen the most recent analyst activity on May 07, 2024, when Jefferies downgraded its rating to a Hold and also revised its price target to $0.50 from $10. Previously, H.C. Wainwright downgraded its rating to Neutral on May 07, 2024, and dropped its price target to $2. On May 07, 2024, downgrade downgraded it’s rating to Underperform. William Blair downgraded its rating to a Mkt Perform. H.C. Wainwright started tracking with a Buy rating for this stock on August 31, 2023, and assigned it a price target of $12. In a note dated May 24, 2022, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $15 on this stock.
Lyra Therapeutics Inc [LYRA] stock has fluctuated between $0.25 and $6.79 over the past year. Currently, Wall Street analysts expect the stock to reach $0.5 within the next 12 months. Lyra Therapeutics Inc [NASDAQ: LYRA] shares were valued at $0.33 at the most recent close of the market. An investor can expect a potential return of 51.52% based on the average LYRA price forecast.
Analyzing the LYRA fundamentals
Lyra Therapeutics Inc [NASDAQ:LYRA] reported sales of 1.68M for the trailing twelve months, which represents a growth of 29.76%. Gross Profit Margin for this corporation currently stands at -12.92% with Operating Profit Margin at -43.65%, Pretax Profit Margin comes in at -40.96%, and Net Profit Margin reading is -41.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.79 and Total Capital is -0.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2913 points at the first support level, and at 0.2527 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3563, and for the 2nd resistance point, it is at 0.3827.
Ratios To Look Out For
For context, Lyra Therapeutics Inc’s Current Ratio is 4.78. Further, the Quick Ratio stands at 4.78, while the Cash Ratio is 0.84. Considering the valuation of this stock, the price to sales ratio is 11.97, the price to book ratio is 0.26.
Transactions by insiders
Recent insider trading involved Waksal Harlan, Executive Chair, that happened on Nov 10 ’23 when 25000.0 shares were purchased.
